Home › Research › Down syndrome and Alzheimer's
GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome
Chu J, Wisniewski T, Praticò D.. Annals of neurology, 2015-10-29
Topic: Brain proteins, microglia and lab models
Plain-language summary
Because of an extra copy of the Aβ precursor protein gene on chromosome 21, Down syndrome (DS) individuals develop high levels of Aβ peptides and Alzheimer disease-like brain amyloidosis early in life. Here we show that the γ-secretase activating protein (GSAP), a key enzyme in amyloidogenesis, is increased in DS brains and specifically regulated at the transcriptional level by GATA1 transcription factor. The discovery of this novel pathway has translational implications for DS, because pharmacological inhibition of GSAP is an attractive and viable Aβ-lowering therapeutic strategy for this disorder.
What this study adds
Evidence grade: Low
The γ-secretase activating protein was found to be increased in Down syndrome brains and regulated by the GATA1 transcription factor. Its stated limit: The abstract does not state the sample size of brain tissue examined, and as a mechanistic tissue study, it does not by itself show whether targeting GATA1 or GSAP would be safe or effective as a treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chu, J., Wisniewski, T., & Praticò, D. (2016). GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome. Annals of neurology. https://doi.org/10.1002/ana.24540
Vancouver
Chu J, Wisniewski T, Praticò D. GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome. Annals of neurology. 2016. doi:10.1002/ana.24540. PMID: 26448035.
BibTeX
@article{chu2016-26448035,
author = {Chu, J. and Wisniewski, T. and Praticò, D.},
title = {{GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome}},
journal = {Annals of neurology},
year = {2016},
doi = {10.1002/ana.24540},
pmid = {26448035},
url = {https://doi.org/10.1002/ana.24540}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Because of an extra copy of the Aβ precursor protein gene on chromosome 21, Down syndrome (DS) individuals develop high levels of Aβ peptides and Alzheimer disease-like brain amyloidosis early in life.
- Here we show that the γ-secretase activating protein (GSAP), a key enzyme in amyloidogenesis, is increased in DS brains and specifically regulated at the transcriptional level by GATA1 transcription factor.
- The discovery of this novel pathway has translational implications for DS, because pharmacological inhibition of GSAP is an attractive and viable Aβ-lowering therapeutic strategy for this disorder.
Why it matters
The γ-secretase activating protein was found to be increased in Down syndrome brains and regulated by the GATA1 transcription factor. The authors say pharmacological inhibition of GSAP is an attractive potential Aβ-lowering strategy, but this is a laboratory finding and no treatment was tested in patients.
Study details
- Evidence strengthLow
Limitations
The abstract does not state the sample size of brain tissue examined, and as a mechanistic tissue study, it does not by itself show whether targeting GATA1 or GSAP would be safe or effective as a treatment.
How this study scored 38/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 17 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.4 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Domenico Praticò: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | New York University: institution h-index 1,612 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26448035) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.